You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCefdinir
Accession NumberDB00535  (APRD00644)
TypeSmall Molecule
GroupsApproved
DescriptionCefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.
Structure
Thumb
Synonyms
(6R,7R,Z)-7-(2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir
Cefdinirum
CFDN
External Identifiers
  • CI 983
  • FK 482
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CefdinirPowder, for suspension250 mg/5mLOralNorth Star Rx Llc2007-12-14Not applicableUs
CefdinirCapsule300 mg/1OralPd Rx Pharmaceuticals, Inc.2011-01-14Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralTeva Pharmaceuticals USA Inc2007-05-08Not applicableUs
CefdinirCapsule300 mg/1OralA S Medication Solutions2008-01-07Not applicableUs
CefdinirCapsule300 mg/1OralRed Pharm Drug, Inc.2007-04-06Not applicableUs
CefdinirCapsule300 mg/1OralTeva Pharmaceuticals USA Inc2007-05-09Not applicableUs
CefdinirCapsule300 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-17Not applicableUs
CefdinirCapsule300 mg/1OralBlue Point Laboratories2014-02-07Not applicableUs
CefdinirCapsule300 mg/1OralCitron Pharma LLC2008-01-07Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralLUPIN LIMITED2007-05-01Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralRebel Distributors Corp2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralDAVA Pharmaceuticals Inc2014-05-01Not applicableUs
CefdinirCapsule300 mg/1OralPd Rx Pharmaceuticals, Inc.2014-07-04Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralA S Medication Solutions2007-12-14Not applicableUs
CefdinirCapsule300 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
CefdinirCapsule300 mg/1OralPhysicians Total Care, Inc.2007-05-08Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralLupin Pharmaceuticals, Inc.2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralA S Medication Solutions2014-05-01Not applicableUs
CefdinirCapsule300 mg/1OralRebel Distributors Corp2008-01-07Not applicableUs
CefdinirCapsule300 mg/1OralAurobindo Pharma Limited2008-01-07Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralOrchid Pharma Inc2013-10-04Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralClinical Solutions Wholesale2007-12-14Not applicableUs
CefdinirCapsule300 mg/1OralSandoz Inc2007-04-06Not applicableUs
CefdinirCapsule300 mg/1OralH.J. Harkins Company, Inc.2008-08-23Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralDispensing Solutions, Inc.2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralPreferred Pharmaceuticals Inc.2016-08-23Not applicableUs
CefdinirCapsule300 mg/1OralRebel Distributors Corp2011-01-14Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralDAVA Pharmaceuticals Inc2014-05-01Not applicableUs
CefdinirCapsule300 mg/1OralPreferred Pharmaceuticals Inc.2015-08-20Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralA S Medication Solutions2007-05-08Not applicableUs
CefdinirCapsule300 mg/1OralNorth Star Rx Llc2008-01-07Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralPhysicians Total Care, Inc.2007-05-08Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralLupin Pharmaceuticals, Inc.2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralLUPIN LIMITED2007-05-01Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralRebel Distributors Corp2007-12-14Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralAurobindo Pharma Limited2007-12-14Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralOrchid Pharma Inc2013-10-04Not applicableUs
CefdinirCapsule300 mg/1OralProficient Rx LP2014-07-04Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralSandoz Inc2007-04-06Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralA S Medication Solutions Llc2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralAvera Mc Kennan Hospital2015-02-27Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralA S Medication Solutions2014-05-01Not applicableUs
CefdinirCapsule300 mg/1OralPd Rx Pharmaceuticals, Inc.2007-05-01Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralDAVA Pharmaceuticals Inc2014-05-01Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralProficient Rx LP2007-05-08Not applicableUs
CefdinirCapsule300 mg/1OralA S Medication Solutions2007-05-09Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralNorth Star Rx Llc2007-12-14Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralPhysicians Total Care, Inc.2007-05-09Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralTeva Pharmaceuticals USA Inc2007-05-08Not applicableUs
CefdinirPowder, for suspension125 mg/5mLOralLUPIN LIMITED2007-05-01Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralAidarex Pharmaceuticals LLC2007-05-01Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralAurobindo Pharma Limited2007-12-14Not applicableUs
CefdinirCapsule300 mg/1OralPd Rx Pharmaceuticals, Inc.2014-07-04Not applicableUs
CefdinirCapsule300 mg/1OralREMEDYREPACK INC.2016-01-18Not applicableUs
CefdinirPowder, for suspension250 mg/5mLOralSandoz Inc2007-04-06Not applicableUs
CefdinirCapsule300 mg/1OralA S Medication Solutions Llc2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralLupin Pharmaceuticals, Inc.2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-05-01Not applicableUs
CefdinirCapsule300 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-10Not applicableUs
CefdinirCapsule300 mg/1OralRed Pharm Drug Inc.2007-05-01Not applicableUs
CefdinirCapsule300 mg/1OralOrchid Pharma Inc2014-07-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CednirAbbott
CefdielRanbaxy
CefzonAstellas
DuocefRanbaxy
EfdinirIncepta
IdinirInvision
KefnirGlenmark
NirocefSel-J
OcephZuventus
OmicefSel-J
OmnicefAbbott Laboratories
Omnicef RJanssen
PalacefRenata
PalcefRenata
RtistLupin
SamnirSiam Bheasach
Xi Fu NiCentral Pharm
ZefdinirZydus
ZinirFDC
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cefdinir monohydrate
ThumbNot applicableDBSALT001745
Categories
UNIICI0FAO63WC
CAS number91832-40-5
WeightAverage: 395.414
Monoisotopic: 395.035809931
Chemical FormulaC14H13N5O5S2
InChI KeyRTXOFQZKPXMALH-GHXIOONMSA-N
InChI
InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
IUPAC Name
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(C=C)=C(N1C(=O)[[email protected]]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Pharmacology
IndicationFor the treatment of the respiratory, skin, soft tissue, and ENT infections caused by H. influenzae (including b-lactamase producing strains), H. parainfluenzae (including b-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains), S. pyogenes, S. aureus (including b-lactamase producing strains), and M. catarrhalis.
Structured Indications
PharmacodynamicsCefdinir is a third generation cephalosporin with a broad spectrum of activity against enteric gram-negative rods. Cefdinir is stable in the presence of some, but not all, b-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal.
Mechanism of actionAs with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis by acting on penicillin binding proteins (PBPs).
TargetKindPharmacological actionActionsOrganismUniProt ID
Penicillin-binding protein 2Proteinyes
inhibitor
Neisseria gonorrhoeaeP08149 details
PBP3Proteinyes
inhibitor
Haemophilus influenzaeQ60FT7 details
MyeloperoxidaseProteinno
inhibitor
HumanP05164 details
Related Articles
AbsorptionMaximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Absorption is reduced by approximately 15% when administered with a high fat meal.
Volume of distribution
  • 0.35±0.29 L/kg [adult subjects]
  • 0.67±0.38 L/kg [pediatric subjects (age 6 months to 12 years)]
Protein binding60%-70%, binding is independent of concentration.
Metabolism

Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug.

Route of eliminationCefdinir is not appreciably metabolized. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t½) of 1.7 (±0.6) hours.
Half life1.7 ± 0.6 hours
Clearance
  • renal cl=2 +/- 1 mL/min/kg [healthy]
ToxicityInformation on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600-mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other b-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.
Affected organisms
  • Enteric gram-negative rods
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Cefdinir.Investigational
Ferric CarboxymaltoseThe serum concentration of Cefdinir can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Cefdinir can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Cefdinir can be decreased when it is combined with Ferric pyrophosphate.Approved
IronThe serum concentration of Cefdinir can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Cefdinir can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Cefdinir can be decreased when it is combined with Iron saccharate.Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefdinir.Approved
Food Interactions
  • Avoid taking antacids at same time (up to 2 hours before or after antibiotic).
  • Avoid taking iron preparations at same time (up to 2 hours before or after antibiotic).
  • Take without regard to meals.
References
Synthesis Reference

Gwan Sun Lee, Young Kil Chang, Jong Pil Chun, Joon Hyung Koh, “Process for preparation of cefdinir.” U.S. Patent US6093814, issued December, 1995.

US6093814
General References
  1. Yamanaka H, Shimazaki J, Imai K, Sugiyama Y, Shida K: Effect of estrogen administration on activities of testosterone 5alpha-reductase, alkaline phosphatase and arginase in the ventral and the dorsolateral prostates of rats. Endocrinol Jpn. 1975 Aug;22(4):297-302. [PubMed:1201739 ]
External Links
ATC CodesJ01DD15
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (69.2 KB)
MSDSDownload (57 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7692
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7205
P-glycoprotein substrateNon-substrate0.5185
P-glycoprotein inhibitor INon-inhibitor0.9298
P-glycoprotein inhibitor IINon-inhibitor0.9165
Renal organic cation transporterNon-inhibitor0.8919
CYP450 2C9 substrateNon-substrate0.8676
CYP450 2D6 substrateNon-substrate0.8203
CYP450 3A4 substrateNon-substrate0.5821
CYP450 1A2 substrateNon-inhibitor0.7603
CYP450 2C9 inhibitorNon-inhibitor0.8303
CYP450 2D6 inhibitorNon-inhibitor0.894
CYP450 2C19 inhibitorNon-inhibitor0.8044
CYP450 3A4 inhibitorNon-inhibitor0.8436
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.953
Ames testNon AMES toxic0.6686
CarcinogenicityNon-carcinogens0.8339
BiodegradationNot ready biodegradable0.9925
Rat acute toxicity1.8801 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9878
hERG inhibition (predictor II)Non-inhibitor0.8964
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aurobindo pharma ltd
  • Lupin ltd
  • Orchid healthcare
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
CapsuleOral300 mg/1
Powder, for suspensionOral125 mg/5mL
Powder, for suspensionOral250 mg/5mL
Prices
Unit descriptionCostUnit
Omnicef 125 mg/5ml Suspension 100ml Bottle101.59USD bottle
Cefdinir 125 mg/5ml Suspension 60ml Bottle53.05USD bottle
Omnicef 300 mg capsule6.31USD capsule
Omnicef 300 mg omni-pac capsule5.72USD capsule
Cefdinir 300 mg capsule5.22USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4935507 No1994-12-042011-12-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-0.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0878 mg/mLALOGPS
logP0.02ALOGPS
logP-1.7ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)1.74ChemAxon
pKa (Strongest Basic)7.45ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area158.21 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.34 m3·mol-1ChemAxon
Polarizability36.12 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassLactams
Sub ClassBeta lactams
Direct ParentCephalosporins
Alternative Parents
Substituents
  • Cephalosporin
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid or derivatives
  • 2,4-disubstituted 1,3-thiazole
  • Primary aromatic amine
  • Meta-thiazine
  • Heteroaromatic compound
  • Thiazole
  • Tertiary carboxylic acid amide
  • Ketoxime
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azetidine
  • Azacycle
  • Dialkylthioether
  • Hemithioaminal
  • Thioether
  • Oxime
  • Monocarboxylic acid or derivatives
  • Enamine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Neisseria gonorrhoeae
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Synthesis of cross-linked peptidoglycan from the lipid intermediates.
Gene Name:
penA
Uniprot ID:
P08149
Molecular Weight:
63649.54 Da
References
  1. Ochiai S, Sekiguchi S, Hayashi A, Shimadzu M, Ishiko H, Matsushima-Nishiwaki R, Kozawa O, Yasuda M, Deguchi T: Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60. Epub 2007 May 31. [PubMed:17540669 ]
Kind
Protein
Organism
Haemophilus influenzae
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Not Available
Gene Name:
pbp3
Uniprot ID:
Q60FT7
Molecular Weight:
67295.025 Da
References
  1. Sanbongi Y, Suzuki T, Osaki Y, Senju N, Ida T, Ubukata K: Molecular evolution of beta-lactam-resistant Haemophilus influenzae: 9-year surveillance of penicillin-binding protein 3 mutations in isolates from Japan. Antimicrob Agents Chemother. 2006 Jul;50(7):2487-92. [PubMed:16801430 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Labro MT, el Benna J, Charlier N, Abdelghaffar H, Hakim J: Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome. J Immunol. 1994 Mar 1;152(5):2447-55. [PubMed:8133056 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [PubMed:10636865 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH: Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta. 1997 Mar 13;1324(2):296-308. [PubMed:9092716 ]
  2. Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11. [PubMed:9374833 ]
  3. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH: Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta. 1997 Mar 13;1324(2):296-308. [PubMed:9092716 ]
  2. Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11. [PubMed:9374833 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23